Nodal signaling as a developmental therapeutics target in oncology

Aparna Kalyan, Benedito A Carneiro Filho, Sunandana Chandra, Jason B Kaplan, Young Kwang Chae, Maria Matsangou, Mary J.C. Hendrix, Francis Joseph Giles

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

The tumor microenvironment is a vital feature of oncogenesis and tumor progression. There are several parallels between cancer cells and early developmental stem cells, including their plasticity and signaling mechanisms. In early fetal development, Nodal is expressed for endodermal and mesodermal differentiation. This expression has been shown reemerge in the setting of epithelial cancers, such as breast and melanoma. High Nodal expression correlates to an aggressive tumor grade in these malignancies. Nodal signal begins with its interaction with its coreceptor, Cripto-1, leading to activation of Smad2/Smad3 and ultimately downstream transcription and translation. Lefty is the natural inhibitor of Nodal and controls Nodal signaling during fetal development.However, cancer cells lack the presence of Lefty, thus leading to uncontrolled tumor growth. Given this understanding, inhibition of the Nodal pathway offers a new novel therapeutic target in oncology.

Original languageEnglish (US)
Pages (from-to)787-792
Number of pages6
JournalMolecular Cancer Therapeutics
Volume16
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

Neoplasms
Fetal Development
Therapeutics
Tumor Microenvironment
Melanoma
Carcinogenesis
Breast
Stem Cells
Growth

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kalyan, Aparna ; Carneiro Filho, Benedito A ; Chandra, Sunandana ; Kaplan, Jason B ; Chae, Young Kwang ; Matsangou, Maria ; Hendrix, Mary J.C. ; Giles, Francis Joseph. / Nodal signaling as a developmental therapeutics target in oncology. In: Molecular Cancer Therapeutics. 2017 ; Vol. 16, No. 5. pp. 787-792.
@article{1607baa529c34510b9217043e9981728,
title = "Nodal signaling as a developmental therapeutics target in oncology",
abstract = "The tumor microenvironment is a vital feature of oncogenesis and tumor progression. There are several parallels between cancer cells and early developmental stem cells, including their plasticity and signaling mechanisms. In early fetal development, Nodal is expressed for endodermal and mesodermal differentiation. This expression has been shown reemerge in the setting of epithelial cancers, such as breast and melanoma. High Nodal expression correlates to an aggressive tumor grade in these malignancies. Nodal signal begins with its interaction with its coreceptor, Cripto-1, leading to activation of Smad2/Smad3 and ultimately downstream transcription and translation. Lefty is the natural inhibitor of Nodal and controls Nodal signaling during fetal development.However, cancer cells lack the presence of Lefty, thus leading to uncontrolled tumor growth. Given this understanding, inhibition of the Nodal pathway offers a new novel therapeutic target in oncology.",
author = "Aparna Kalyan and {Carneiro Filho}, {Benedito A} and Sunandana Chandra and Kaplan, {Jason B} and Chae, {Young Kwang} and Maria Matsangou and Hendrix, {Mary J.C.} and Giles, {Francis Joseph}",
year = "2017",
month = "5",
day = "1",
doi = "10.1158/1535-7163.MCT-16-0215",
language = "English (US)",
volume = "16",
pages = "787--792",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

Nodal signaling as a developmental therapeutics target in oncology. / Kalyan, Aparna; Carneiro Filho, Benedito A; Chandra, Sunandana; Kaplan, Jason B; Chae, Young Kwang; Matsangou, Maria; Hendrix, Mary J.C.; Giles, Francis Joseph.

In: Molecular Cancer Therapeutics, Vol. 16, No. 5, 01.05.2017, p. 787-792.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Nodal signaling as a developmental therapeutics target in oncology

AU - Kalyan, Aparna

AU - Carneiro Filho, Benedito A

AU - Chandra, Sunandana

AU - Kaplan, Jason B

AU - Chae, Young Kwang

AU - Matsangou, Maria

AU - Hendrix, Mary J.C.

AU - Giles, Francis Joseph

PY - 2017/5/1

Y1 - 2017/5/1

N2 - The tumor microenvironment is a vital feature of oncogenesis and tumor progression. There are several parallels between cancer cells and early developmental stem cells, including their plasticity and signaling mechanisms. In early fetal development, Nodal is expressed for endodermal and mesodermal differentiation. This expression has been shown reemerge in the setting of epithelial cancers, such as breast and melanoma. High Nodal expression correlates to an aggressive tumor grade in these malignancies. Nodal signal begins with its interaction with its coreceptor, Cripto-1, leading to activation of Smad2/Smad3 and ultimately downstream transcription and translation. Lefty is the natural inhibitor of Nodal and controls Nodal signaling during fetal development.However, cancer cells lack the presence of Lefty, thus leading to uncontrolled tumor growth. Given this understanding, inhibition of the Nodal pathway offers a new novel therapeutic target in oncology.

AB - The tumor microenvironment is a vital feature of oncogenesis and tumor progression. There are several parallels between cancer cells and early developmental stem cells, including their plasticity and signaling mechanisms. In early fetal development, Nodal is expressed for endodermal and mesodermal differentiation. This expression has been shown reemerge in the setting of epithelial cancers, such as breast and melanoma. High Nodal expression correlates to an aggressive tumor grade in these malignancies. Nodal signal begins with its interaction with its coreceptor, Cripto-1, leading to activation of Smad2/Smad3 and ultimately downstream transcription and translation. Lefty is the natural inhibitor of Nodal and controls Nodal signaling during fetal development.However, cancer cells lack the presence of Lefty, thus leading to uncontrolled tumor growth. Given this understanding, inhibition of the Nodal pathway offers a new novel therapeutic target in oncology.

UR - http://www.scopus.com/inward/record.url?scp=85020198550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020198550&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-16-0215

DO - 10.1158/1535-7163.MCT-16-0215

M3 - Review article

VL - 16

SP - 787

EP - 792

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 5

ER -